ATRAAtara Biotherapeutics Inc
−4.9% today · −26.0% over a year
No score: too little data.
Quality, Stability: among the weakest. No dividend.
Atara Biotherapeutics Inc (ATRA) belongs to the Health care sector and is listed on Nasdaq; country: United States. Its market value is about €71.2M. Over the past 12 months the price changed by −26.0%, with an annualised volatility of 141% and a largest fall of 77%.
Smart Score
How it is scored →Not scored: not enough data for a fair comparison.
Factor scores
Percentiles within the peer group (100 = the best of its peers); dividend safety in points.
Main drivers
- Volatility (1 y)weighs on the score · better than 2% of peers
- Accrualsweighs on the score · better than 4% of peers
- Share issuance (1 y)weighs on the score · better than 16% of peers
Red flags and notes
- Caution. Negative free cash flow in at least two of the last three years. More in the glossary → Negative free cash flow in at least two of the last three years.
- Caution. Accruals or the Beneish M-score are in the watch zone. More in the glossary → Accruals or the Beneish M-score are in the watch zone.
- Caution. Net debt above 4× EBITDA or interest cover below 2×. More in the glossary → Net debt above 4× EBITDA or interest cover below 2×.
- Caution. Book equity is below zero. More in the glossary → Book equity is below zero.
- Caution. At least one reverse split in the last three years. More in the glossary → At least one reverse split in the last three years.
Price chart
Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.
Key metrics
Valuation
- P/S
- 12.9
- Market cap (EUR)
- €71.2M
Dividends
- Dividend yield
- 0.00%
- Years without a lower dividend
- 0
Returns and risk
- 1 day
- −4.9%
- 1 month
- −15.3%
- 1 year
- −26.0%
- Volatility, 1 yr
- 140.6%
- Max drawdown, 1 yr
- −76.9%
- Beta
- 0.93
Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.
Similar companies
Same sector and region, closest in market value.
| VXRTVaxart Inc | —/10 | 0.0% | 12.1% |
|---|---|---|---|
| FRNMFreenome Inc. | —/10 | 0.0% | −2.4% |
| SKINSkinHealth Systems | 2/10 | 0.0% | −64.8% |
| LENZLENZ Therapeutics, Inc. | 1/10 | 0.0% | −86.0% |
| BDTXBlack Diamond Therapeutics Inc | —/10 | 0.0% | −57.1% |
| AVXLAnavex Life Sciences Corp. | —/10 | 0.0% | −84.8% |
| HCATHealth Catalyst | 1/10 | 0.0% | −50.8% |
| CHRSCoherus Oncology | —/10 | 0.0% | −52.1% |
News and filings
- Atara Biotherapeutics, Inc.: 10-Q — Quarterly report for the period ending 30 Jun 2026
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 12 Aug 2026
- Atara Biotherapeutics, Inc.: 8-K — Results of operations
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 12 Aug 2026
What the marks mean
- FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
- Media reportA headline from a named media outlet. We link to it and do not check it.
- RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.
Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.
Score changes in the last 12 months
Every published rating and change, logged when it was published (EU Market Abuse Regulation).
Show the log: 1 entry
| Date | Event | Balanced | Growth · Income | Warnings | Price at publication |
|---|---|---|---|---|---|
| First rating | —/10 | — · — | Available with Invest Pro |
Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.
Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.